The Claim

Daily administration of 10 mg rosuvastatin for a median of 32.8 months in older adults (aged 60+) with ischemic systolic heart failure and reduced ejection fraction significantly reduced cardiovascular hospitalizations by 154 fewer events per 1000 patients compared to placebo, despite no significant reduction in death or major cardiovascular events.

Source: Rosuvastatin in older patients with systolic heart failure.

What the research says

Supports is higher

Support is ahead, but a single strong opposing study can change this.

Supports
72score
Challenges
0score

These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.

Cause and effect
1 study reviewed
In plain English

In older adults with a specific type of heart failure, taking 10 mg of rosuvastatin daily for about 33 months led to 154 fewer hospitalizations for cardiovascular problems per 1000 people compared to those taking a placebo, even though it did not reduce deaths or major cardiovascular events.

See the scientific wording

In older adults (aged 60+) with ischemic systolic heart failure and reduced ejection fraction, daily administration of 10 mg rosuvastatin for a median of 32.8 months significantly reduced cardiovascular hospitalizations by 154 fewer events per 1000 patients compared to placebo, despite no significant reduction in death or major cardiovascular events, indicating a clinically meaningful benefit in reducing disease-related morbidity.

Why this might work

Rosuvastatin blocks a key enzyme in the liver that makes cholesterol, which lowers bad cholesterol and reduces inflammation in the blood. This lowers a protein called CRP that signals widespread inflammation. Less inflammation means the blood vessels work better, allowing more oxygen to reach the heart muscle. This prevents sudden worsening of heart failure that leads to hospital visits.

Verified mechanismbased on 1 study

What the research says

1 study

  1. Study: Rosuvastatin in older patients with systolic heart failure.

    Taking rosuvastatin didn't stop older heart failure patients from dying or having heart attacks, but it did keep them out of the hospital more often—about 154 fewer hospital visits per 1000 patients over nearly 3 years.

Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies

Fit Body Science verdict — we translate health claims into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.